Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier

The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However, DPP4 mutations in humans or the long-term outcomes of high glucagon-like peptide-1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Endocrinol (Lausanne)
Hauptverfasser: Zhao, Dandan, Zhao, Shaoqian, Wang, Xiao, Su, Mingbo, Liu, Wen, Ma, Qinyun, Hong, Jie, Gu, Weiqiong, Li, Jingya, Liu, Ruixin, Ning, Guang, Wang, Jiqiu, Zhang, Yifei
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2018
Schlagworte:
Endocrinology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845420/
https://ncbi.nlm.nih.gov/pubmed/29556215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00062
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge